Jump to ContentJump to Main Navigation
Show Summary Details

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter / Tate, Jillian R.

12 Issues per year


IMPACT FACTOR increased in 2015: 3.017
Rank 5 out of 30 in category Medical Laboratory Technology in the 2014 Thomson Reuters Journal Citation Report/Science Edition

SCImago Journal Rank (SJR) 2015: 0.873
Source Normalized Impact per Paper (SNIP) 2015: 0.982
Impact per Publication (IPP) 2015: 2.238

Online
ISSN
1437-4331
See all formats and pricing
Volume 49, Issue 10 (Oct 2011)

Issues

Clinical significance of pleural effusion mesothelin in malignant pleural mesothelioma

Shusai Yamada
  • Division of Respiratory Medicine, Department of Internal Medicine, Hyogo College of Medicine, Hyogo, Japan
  • Shusai Yamada and Chiharu Tabata contributed equally to this study.
/ Chiharu Tabata
  • Division of Respiratory Medicine, Department of Internal Medicine, Hyogo College of Medicine, Hyogo, Japan
  • Shusai Yamada and Chiharu Tabata contributed equally to this study.
  • Email:
/ Rie Tabata
  • Department of Internal Medicine, Hyogo Prefectural Tsukaguchi Hospital, Hyogo, Japan
/ Kazuya Fukuoka
  • Division of Respiratory Medicine, Department of Internal Medicine, Hyogo College of Medicine, Hyogo, Japan
/ Takashi Nakano
  • Division of Respiratory Medicine, Department of Internal Medicine, Hyogo College of Medicine, Hyogo, Japan
Published Online: 2011-06-22 | DOI: https://doi.org/10.1515/CCLM.2011.242

Abstract

Background: Malignant pleural mesothelioma (MPM) is an aggressive malignant tumor of mesothelial origin associated with asbestos exposure. MPM has a limited response to conventional chemotherapy and radiotherapy, so early diagnosis of MPM is very important. This study investigated the pleural effusion mesothelin levels in patients with MPM and compared them to those of a population with a non-malignant pleuritis or lung cancer involving malignant pleural effusion.

Methods: The pleural effusion mesothelin concentrations were measured in 45 MPM patients and 53 non-MPM individuals (24 individuals with non-malignant pleural effusions and 29 individuals with lung cancer involving malignant pleural effusion).

Results: This study demonstrated that patients with MPM had significantly higher pleural effusion mesothelin levels than a population with non-malignant pleuritis or lung cancer involving malignant pleural effusion. The difference in overall survival between the groups with pleural effusion mesothelin levels lower and higher than the assumed cut-off of 10 nM was significant.

Conclusions: The data suggest that the pleural effusion mesothelin concentration could be useful as an aid for the diagnosis of MPM.

Keywords: mesothelin; mesothelioma; tumor marker

About the article

Corresponding author: Chiharu Tabata, MD, PhD, Division of Respiratory Medicine, Department of Internal Medicine, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo 663-8501, Japan Phone: +81-798-45-6596, Fax: +81-798-45-6597


Received: 2010-12-17

Accepted: 2011-05-20

Published Online: 2011-06-22

Published in Print: 2011-10-01


Citation Information: Clinical Chemistry and Laboratory Medicine, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/CCLM.2011.242. Export Citation

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Arnold M. Schwartz and M. Katayoon Rezaei
Chest, 2013, Volume 143, Number 5, Page e251S
[3]
V. Panou, M. Vyberg, U.M. Weinreich, C. Meristoudis, U.G. Falkmer, and O.D. Røe
Cancer Treatment Reviews, 2015, Volume 41, Number 6, Page 486
[4]
Jenette Creaney, Amanda Segal, Nola Olsen, Ian M. Dick, A. W(Bill) Musk, Steven J. Skates, and Bruce W. Robinson
Disease Markers, 2014, Volume 2014, Page 1
[5]
Jenette Creaney, Ian M. Dick, Amanda Segal, Arthur W. Musk, and Bruce W.S. Robinson
Lung Cancer, 2013, Volume 82, Number 3, Page 491
[6]
Pier Aldo Canessa, Paola Ferro, Carmen Manta, Massimiliano Sivori, Maria Cristiana Franceschini, Franco Fedeli, and Silvio Roncella
Medical Oncology, 2013, Volume 30, Number 3
[7]
Pier Aldo Canessa, Maria Cristiana Franceschini, Paola Ferro, Enrico Battolla, Paolo Dessanti, Carmen Manta, Massimiliano Sivori, Riccardo Pezzi, Vincenzo Fontana, Franco Fedeli, Maria Pia Pistillo, and Silvio Roncella
Cancer Investigation, 2013, Volume 31, Number 1, Page 43
[8]
Enrico Battolla, Pier Aldo Canessa, Paola Ferro, Antonella Vigani, Vincenzo Fontana, Maria Cristiana Franceschini, Carmen Manta, Paolo Dessanti, Gianluca Masini, Rita Lanzoni, Fabrizio Via, Rosamaria Cocilovo, Franco Fedeli, Maria Pia Pistillo, and Silvio Roncella
La Rivista Italiana della Medicina di Laboratorio - Italian Journal of Laboratory Medicine, 2012, Volume 8, Number 2, Page 94
[9]
Seiki Hasegawa, Nobuyuki Kondo, Seiji Matsumoto, Teruhisa Takuwa, Masaki Hashimoto, Hayato Orui, Shunichi Fukuda, Kazue Yoneda, Yoshitomo Okumura, Noriaki Tsubota, Kazuya Fukuoka, Ikuko Torii, Tohru Tsujimura, and Takashi Nakano
International Journal of Clinical Oncology, 2012, Volume 17, Number 1, Page 33
[10]
Elad Sharon, Jingli Zhang, Kevin Hollevoet, Seth M. Steinberg, Ira Pastan, Masanori Onda, Jochen Gaedcke, B. Michael Ghadimi, Thomas Ried, and Raffit Hassan
Clinical Chemistry and Laboratory Medicine, 2012, Volume 50, Number 4

Comments (0)

Please log in or register to comment.
Log in